Clinical

The AJMC^® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care^® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.

Latest News

On-body delivery system | Image credit: Enable Injections

Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?

By Mary Caffrey

June 6th 2025

Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.

Atopic Dermatitis Image Credit: wladimir1804-stock.adobe.com

Oral Ivarmacitinib Shows Promise in Atopic Dermatitis

By Maggie L. Shaw

June 6th 2025

Doctor holding "bronchiectasis" board | Image Credit: MQ-Illustrations - stock.adobe.com

ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils

By Brooke McCormick

June 6th 2025

FDA headquarters | Image Credit: - Tada Images- stock.adobe.com

5 Key FDA Approval Dates Mark a Milestone-Filled May

By Brooke McCormick

June 6th 2025

The findings support the use of luspatercept as the first-line standard of care for anemia treatment in patients with MDS. | Image Credit: wanchalerm - stock.adobe.com

Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS

By Rose McNulty

June 5th 2025

More News

Reimbursement of Subcutaneous Versus IV Dosing in Multiple Myeloma

June 28th 2019

Watch

OCM Ensures Better Outcomes and Automatic Cost Savings in Multiple Myeloma

June 28th 2019

Watch

The Impact of OCM in the Treatment of Multiple Myeloma

June 28th 2019

Watch

Entering a 4-Drug Regimen for Multiple Myeloma Treatment

June 28th 2019

Watch

MAIA Trial: Transplant-Ineligible Patients With MM

June 28th 2019

Watch

Using MRD Negativity to Stop Maintenance Therapy in MM

June 28th 2019

Watch

Long-term Data on Improving OS for Patients With MM

June 28th 2019

Watch

Payer Perspective: Transplant and Toxicities in MM Therapy

June 28th 2019

Watch

FORTE Trial: Transplant in Patients with Multiple Myeloma

June 28th 2019

Watch

Impact of Maintenance Therapy in Multiple Myeloma

June 28th 2019

Watch

Strategy for Up-front Therapy of Multiple Myeloma

June 28th 2019

Watch

Backbone Therapy in Newly Diagnosed Multiple Myeloma

June 28th 2019

Watch

How Real-World Data Can Address Problems in MM

June 28th 2019

Watch

$Dosing Strategies in Relapsed-Refractory MM$

Dosing Strategies in Relapsed-Refractory MM

June 28th 2019

Watch

$Initiating Treatment in Relapsed-Refractory MM$

Initiating Treatment in Relapsed-Refractory MM

June 28th 2019

Watch

What Is the Cost of Recurrence in Multiple Myeloma?

June 28th 2019

Watch

Daratumumab in the Treatment Landscape for MM

June 28th 2019

Watch

Clinical Significance of MRD Testing in MM

June 28th 2019

Watch

Practical Implications of the MAIA Study for MM

June 28th 2019

Watch

Considerations for Transplant-Ineligible Patients

June 28th 2019

Watch

NCCN Guidelines for Newly Diagnosed MM

June 28th 2019

Watch

Achieving the Best Outcomes for Patients With MM

June 28th 2019

Watch

Cost Considerations of Multidrug Regimens in MM

June 28th 2019

Watch

Factoring Age Into Frontline Therapy for MM

June 28th 2019

Watch

Individualizing Therapy for Multiple Myeloma Patients

June 28th 2019

Watch

June Halper Outlines the Biggest Management Challenges in Multiple Sclerosis

June 22nd 2019

The biggest clinical challenges that we have in treating multiple sclerosis are 2-fold, explained June Halper, MSN, APN-C, MSCN, FAAN, chief executive officer, Consortium of Multiple Sclerosis Centers.

Watch

Evaluating Use of Bone-Modifying Agents to Treat Skeletal-Related Events in Cancer

Laura Joszt, MA

June 15th 2019

Skeletal-related events are frequent complications in patients with cancers. Two abstracts analyzed the use of bone-modifying agents in patients with newly diagnosed multiple myeloma and breast cancer.

Identifying Biomarkers to Predict Disease Severity, Progression, and Cognitive Impairment in MS

Laura Joszt, MA

June 6th 2019

Two abstracts presented at the 33rd Annual Meeting of the Consortium of Multiple Sclerosis Centers analyzed biomarkers to predict progression, disease severity, and cognitive impairment in multiple sclerosis (MS).